Omnicell (NASDAQ:OMCL) Issues Q3 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its third quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.300-0.370 for the period, compared to the consensus estimate of 0.304. The company issued revenue guidance of $290.0 million-$300.0 million, compared to the consensus revenue estimate of $284.1 million. Omnicell also updated its FY 2025 guidance to 1.400-1.650 EPS.

Omnicell Trading Up 1.7%

OMCL traded up $0.51 during trading on Monday, reaching $30.27. 48,591 shares of the stock traded hands, compared to its average volume of 564,751. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.42 billion, a PE ratio of 60.50, a P/E/G ratio of 8.69 and a beta of 0.78. The stock's 50-day moving average is $29.27 and its 200 day moving average is $33.05. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 EPS. Equities analysts anticipate that Omnicell will post 1.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Benchmark cut their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company increased their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $45.33.

Hedge Funds Weigh In On Omnicell

Several large investors have recently added to or reduced their stakes in OMCL. Empowered Funds LLC lifted its position in shares of Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock worth $348,000 after buying an additional 1,243 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after buying an additional 5,311 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after buying an additional 4,866 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after buying an additional 109,382 shares in the last quarter. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.